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ABSTRACT 
Synovial sarcoma is a rare but aggressive paediatric soft tissue sarcoma that is driven by 
the genomic rearrangement t(X;18)(p11.2;q11.2). The resulting fusion protein, SS18-
SSX, exhibits oncogenic properties through protein-protein interactions that alter gene 
transcriptions and chromatin remodelling. Synovial sarcomas respond poorly to the 
conventional chemotherapies. Hence, it is necessary to develop novel therapeutic 
targets to improve the outcome of the treatment in synovial sarcoma. Considering that 
the expression of the fusion protein SS18-SSX is specific and essential for synovial 
sarcoma development and survival, targeting this chimeric oncoprotein or its functional 
protein network is a potential therapeutic strategy. To date there are no known 
compounds that directly target SS18-SSX, the driving fusion protein of synovial 
sarcoma.   
SS18 is a transcriptional activator, member of the SWI/SNF complex that is 
ubiquitously expressed in normal cells. In the SS18-SSX fusion protein, the last nine 
amino acids of SS18 are replaced by 78 C-terminal amino acids of SSX. The resultant 
fusion protein therefore inherits oncogenic activities that are independent of the wild 
type SS18 and SSX. It recruits proteins that are involved in epigenetic gene regulation 
such as histone deacetylases and polycomb group proteins to form a fusion protein 
complex that regulates gene transcription and subsequently drives malignant 
transformation.  
The work in this thesis explores the role of two class III histone deacetylases, SIRT1 
and SIRT2, in the proliferation and survival of synovial sarcoma. We found that SIRT1 
is overexpressed in primary synovial sarcomas. Both siRNA mediated and 
pharmacological knock down of SIRT1 and SIRT2 in synovial sarcomas and 
rhabdomyosarcomas impairs cell proliferation and autophagy flux. The overexpression 
of SIRT1 in synovial sarcomas was not associated with the clinical outcome of patients. 
However, in experimental in vitro cell assays, we observed that nutrient deprivation 
enhanced the sensitivity of synovial sarcoma and rhabdomyosarcoma cells to sirtuin 
inhibition. These results suggest a role of SIRT1 and SIRT2 in tumor cell survival under 
conditions of nutrient deficiency.  
Mechanistically, we found that SIRT1 and SIRT2 form a complex with SS18-SSX and 
their histone substrate H4K16ac in a synovial sarcoma cell line and a patient-derived 
synovial sarcoma. This complex is disrupted shortly after exposure to the sirtuin 
inhibitors tenovin-6 and AGK2. These findings indicate that the interactions between 
SIRT1/SIRT2 and SS18-SSX may contribute to the malignant phenotype of synovial 
sarcoma by modifying acetylation of the SIRT1 and SIRT2 substrate, H4K16. The 
acetylation of H4K16 is associated with autophagy. Future studies should address 
whether autophagy genes are targets of the SS18-SSX/SIRT1/SIRT2 complex.   
  VIII 
We set up a proximity ligation assay (PLA) as a screening method to search for small 
compounds that disrupt the SS18-SSX fusion protein complex. We first validated the 
method and showed that the association of SS18-SSX with TLE1 is specific for 
synovial sarcoma and can be visualised by PLA. We then screened a library of 16000 
molecules and identified class I HDAC inhibitors and a novel compound, SXT1596, as 
agents that are able to dissociate the SS18-SSX/TLE1 complex and induce apoptosis in 
synovial sarcomas. We further showed that the disruption of the SS18-SSX/TLE1 
complex by SXT1596 in synovial sarcoma released repression of EGR1 and rescued 
normal signaling.  
The studies in this thesis provide direct evidences that SS18-SSX interacts with proteins 
that regulate transcription by epigenetic modification of targets, such as class I histone 
deacetylases and sirtuins. The disruption of the SS18-SSX protein complex with small 
molecular HDAC inhibitors induces rapid death of synovial sarcoma cells proving that 
targeting the driving complex of synovial sarcoma may give an opportunity to develop 
effective therapies for synovial sarcoma patients. Furthermore, PLA based drug 
screening is shown to be a reliable and valuable technique to identify lead compounds 
that disrupt protein-protein interactions and could be applied in other cancer types that 
are driven by fusion transcription factors. 
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1 INTRODUCTION 
1.1 SARCOMA 
Our body can be viewed as a complicated machine in which numerous cells form different 
modules and perform specialized functions 1. All cells arise through the division of pre-
existing cells and then differentiating to various specialized tissues 2.  This system is not 
foolproof and mistakes are being made during the cell division process, DNA mutations 
accumulate and the cell fails to recognise them causing cells to mutate. The mutated cells 
therefore gain malignant traits such as proliferating unlimitedly, resisting cell death, escaping 
from immune surveillance, inducing angiogenesis, activating metastases and enabling 
replicative immortality 3. Dependent on the origin of the cell, human cancers can be 
categorized into 5 major groups. i) Carcinoma is the most commonly diagnosed cancer that 
originates in epithelial tissues such as the skin; ii) Sarcoma is the cancer that arises in 
transformed cells of mesenchymal origin; iii) Leukaemia, originates in blood and bone 
marrow; iv) Lymphoma & myeloma, cancers of lymphocytes; and v) brain & spinal cord 
cancer that occur in the central nervous system. The work in this thesis is limited to sarcoma, 
which is therefore the focus of the following section. 
Sarcomas are aggressive tumors that develop in the connective tissue, including bones, 
muscles, fat, blood vessels, nerves and cartilage. The incidence is slightly higher in males 
than females. Sarcomas are rather common in teenagers where it makes up 15% of all the 
cancers, while for adults it accounts for only 1% of all cancers. Sarcoma can occur in any part 
of the body. It is subdivided into soft tissue sarcoma and bone sarcoma depending on the 
tissue of origin. 
Soft tissue sarcomas are a heterogeneous group of tumors that consist of more than 50 
different histological subtypes. Unlike other types of cancer, which are usually named for the 
part of the body where the cancer began, the terminology of soft tissue sarcomas is often 
dependent on the normal tissue cells they most closely resemble. Soft tissue sarcoma 
comprises less than 1% of all cancers diagnosed each year. Such low morbidity might be 
because of that the connective/soft tissue cells are not continuously dividing compared with 
for example epithelial tissues that give rise to the majority of the human cancers. The most 
common sites of soft tissue sarcomas are extremities, chest, or abdomen, but they can be 
found anywhere in the body and behave clinically different.  
The most common primary malignant bone cancers are osteosarcoma, chondrosarcoma and 
Ewing’s sarcoma. They derive from different parts of bones and metastasize to multiple sites 
in the body. Osteosarcoma accounts for 35% of all bone cancers and arises from primitive 
mesenchymal osteoid tissue, often in the knee and upper arms of children, the most 
susceptible metastatic site is the lung 4. Twenty-five percent of the bone cancers are 
diagnosed as chondrosarcoma, which originates in cartilaginous tissue and is often seen in the 
pelvis, upper legs and shoulders. Ewing’s sarcoma is also called Ewing family of tumours, it 
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consists of several different tumor types and accounts for 16% of bone cancers. Ewing’s 
sarcoma usually forms in the pelvis, femur, ribs and clavicle. The 5-year overall survival rate 
of primary Ewing’s sarcoma is around 70%. For patients with metastatic diseases, this 
survival rate is only 20-30%. The genetic alteration that underlines most of Ewing’s sarcomas 
is the chromosome translocation between chromosome 22 and 11, which results in the fusion 
gene EWS/FLI1 5.  
Table 1. Sarcomas and related chromosome translocations 
Tumor type Translocation Fusion product 
 
 
Alveolar rhabdomyosarcoma 
t(2;13)(q35;q14) 6 PAX3-FOXO1A 
t(1;13)(q36;q14) 6 PAX7-FOXO1A 
t(2;2)(p23;q35) 7 PAX3-NCOA1 
t(2;8)(q35;q13) 7 PAX3-NCOA2 
t(8;13;9)(p11.2;q14;9q32) 8 FGFR1-FOXO1 
Alveolar soft part sarcoma t(X;17)(p11;q25) 9 TFE3-ASPL 
Clear cell sarcoma t(12;22)(p13;q12) 10 EWS-ATF1 
Desmoplastic small-round cell 
tumour 
t(11;22)(p13;q12) 11 EWS-WT1 
t(21;22)(q22;q12) 12 EWS-ERG 
 
 
 
Ewing sarcoma (ES) 
 
t(11;22)(q24;q12) 13 EWS-FLI1 
t(21;22)(q22;q12) 14 EWS-ERG 
t(7;22)(p22;q12) 15 EWS-ETV1 
t(17;22)(q21;q12) 16 EWS-ETV4 
t(2;22)(q33;q12) 17 EWS-FEV 
t(2;16)(q35;p11) 18 FUS-FEV 
t(1;22)(q36.1;q12) 19 EWS-ZSG 
t(4;19)(q35;q13) 20 CIC-DUX4 
 
Inflammatory myofibroblastic 
tumour 
 
t(1;2)(q25;q23) 21 22 TPM3-ALK 
t(2;19)(q23;q13) 22 TPM4-ALK 
t(2;17)(q23;q23) 21 CLTC-ALK 
t(2;2)(p23;q13) 23 RANBP2-ALK 
Low grade fibromyxoid sarcoma 
 
t(7;16)(q33;q11) 24 FUS-CREB3L2 
t(11;16)(q11;q11) 25 FUS-CREB3L1 
Myxoid liposarcoma t(12;16)(q13;q11) 26 FUS-DDIT3 
t(12;22)(q13;q12) 19 EWSR1-DDIT3 
 
Synovial sarcoma 
t(X;18)(p11;q11) 27 SS18-SSX1 
t(X;18)(p11;q11) 27 SS18-SSX2 
t(X;18)(p11;q13) 28 SS18-SSX4 
The etiology of sarcomas is not clear. Nearly 30% of all sarcomas are characterized by 
specific genetic alterations. They either carry specific oncogenic mutations like somatic 
mutations of c-KIT in gastrointestinal stromal tumors (GIST), or are characterized by certain 
chromosomal translocations resulting in the expression of chimeric transcription factors 
(Table 1) 29. The sarcomas with non-specific genetic abnormalities often have unbalanced 
karyotypes and numerous aberrations (such as chromosomal losses and gains), which have 
been identified as driving events. 
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1.1.1 Rhabdomyosarcoma 
The most common peadiatric soft tissue sarcoma is rhabdomyosarcoma (RMS), it originates 
from striated or skeletal muscle cells and develops, most commonly, in the head, neck, 
genitals and extremities 30. RMS is highly aggressive and has a strong tendency for 
recurrence and metastasis. Common metastatic sites are lung, bones and bone marrow 31. It 
has been suggested that in children, below the age of 3, the development of RMS might be 
related with germline mutation of p53 32. Studies also revealed that Beckwith-Wiedemann 
syndrome, a rare genetic disorder due to abnormalities on chromosome 11p15, is related with 
the tumourigenesis of RMS 33. 
RMS is divided into different histological subtypes, in which embryonal RMS (ERMS) and 
alveolar RMS (ARMS) are the most common ones, accounting for ~60% and ~20% of cases, 
respectively. ERMS is characterized by loss of heterozygosity (LOH) on chromosome 11, at 
the location of p15.5. The expression of the genes within this region is epigenetically affected 
by genomic imprinting, which means that one of the alleles inherited from one of the parents 
is silenced. The genes located on the active allele might be inactivated by point mutation, 
leading to the loss of the entire gene. It is postulated that there are tumor suppressor genes 
located in this region. When both alleles of the tumor suppressor are inactive due to a 
combination of genetic imprinting and allelic loss, oncogenic effect is promoted.  
The majority of ARMS carry the chromosomal translocation t(2;13)(q35;q14) which fuses 
the PAX3 gene (paired box 3) located on chromosome 2 to FOXO1 (fork-head box O1 
family, formerly called FKHR) which is located on chromosome 13. Another common 
ARMS translocation is t(1;13)(p36;q14), which fuses PAX7, a PAX family gene located on 
chromosome 1, with FOXO1 6. PAX3-FOXO1 is expressed in approximately 70% of the 
cases while PAX7-FOXO1 in 10-15% and they are referred as P3F and P7F, respectively. 
These fusing proteins play pivotal roles in initiating or enhancing tumourigenesis 34. The 
expression of PAX-FOXO1 fusion protein in ARMS influences the prognosis of the patient. 
For example, the fusion gene-negative ARMS has similar molecular profile with ERMS and 
is less aggressive compared to the ARMS that carries the fusion gene 35,36. Meanwhile, the 
ARMS that carries PAX7-FOXO1 fusion transcript is associated with better prognosis 
compared with the more common PAX3-FOXO1 variant 37,38.  
Still, there are 20-30% of the ARMS that show no sign of PAX-FOXO1 translocations. The 
study of a rare ARMS case has shown that the PAX3 gene is fused with transcriptional 
coactivator NCOA1 or NCOA2 because of the translocations t(2;2)(p23;35) or 
t(2:8)(q35;q13) 7.  Another ARMS case reported in 2011 was identified to have a special 
t(8;13;9)(p11.2;q14;9q32) three-way translocation 8. 
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Figure 1. Chromosomal translocation t(2;13)(q35;q14) in ARMS. 
1.1.2 Synovial sarcoma  
Synovial sarcoma (SS) is the second most commonly diagnosed paediatric soft tissue 
sarcoma. It accounts for 10% of all soft tissue sarcomas and occurs predominantly in 
teenagers and young adults between the age of 15 and 40 39. Despite its name, SS neither 
originates from synovial cells nor differentiates toward synovium 40,41. Instead, it derives 
from myoblastic precursor cells and is able to develop anywhere in the body 42,43. Most SS 
develops in deep soft tissues around the large joints of the extremities, with 60 % -70 % 
occurring around knees. The prognosis of SS is normally poor because of recurrence and 
metastatic diseases. 
Histologically, SSs are divided into biphasic, monophasic and poorly differentiated types. 
The monophasic SS shows the morphology of spindle shaped mesenchymal cells and appears 
to be most frequent in adults (72%). Biphasic SS exhibits both spindle cell morphology and 
foci of epithelial differentiation. However, in children, these 2 subtypes are more equally 
distributed (55% monophasic and 45% biphasic) 43,44. The poorly differentiated variant of SS 
is less common (20%) but normally more aggressive and indicates poor prognosis compared 
to other types. Sometimes small round cells can be observed in poorly differentiated SS, 
which makes it difficult to distinguish this type from other small round cell tumors by 
histology. Therefore extra genotypic analyses are necessary to confirm the diagnosis. 
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1.2 SS18-SSX, THE FUSION ONCOPROTEIN IN SYNOVIAL SARCOMA 
SS is one of the most well understood translocation-associated sarcomas. The characteristic 
translocation t(X;18)(p11.2;q11.2) involves the SS18 gene on chromosome 18 and SSX1, 
SSX2 or SSX4 gene on chromosome X 45, which results in the expression of the aberrant 
fusion protein, SS18-SSX in nearly all SS. It is not known whether this genetic alteration 
happens randomly or follows certain events, but it has been proven that it is necessary and 
sufficient for SS tumor initiation, therefore SS18-SSX is considered as a driver oncogene 27,46 
47. In more than 30% of SS, SS18-SSX is the only cytogenetic anomaly and it remains 
detectable in metastatic diseases. Studies have shown that knock down of the SS18-SSX 
fusion protein decreases SS cells’ viability and induces apoptosis 48. On the other hand, the 
conditional expression of the fusion protein SS18-SSX in a mouse model induces SS with 
100% penetrance 42. Several Studies have shown that the SSX fusion type has impact on the 
clinical behaviour of SS. Patients with tumours expressing the SS18-SSX1 fusion gene have 
worse clinical outcomes. However, there is one study showing contradictory results where the 
fusion type shows no impact on the survival of SS patients 49.   
SS18 
Wild type SS18 (formerly named SSXT, SYT) is an ubiquitously expressed gene located on 
the long arm of chromosome 18 (at position q11.2). It encodes a transcriptional activator that 
contains 418 amino acids. The highly conserved N-terminal domain of SS18, which is 
designated as SNH domain, is composed of 54 amino acids and is responsible for the nuclear 
localisation of SS18 50. The C-terminal of SS18 is designated as the QPGY domain, which 
represents the amino acid glutamine, proline, glycine, and tyrosine in this region. The mutants 
bearing the QPGY deletion show a decreased transcriptional activation potential of SS18 23,51. 
SS18 has no DNA binding motifs, but contains many potential protein-protein interaction 
sites and functions as a transcriptional activator by interacting with DNA binding proteins. 
These proteins are involved in chromatin modification and gene expression 50, such as 
members of the SWI/SNF complex, histone acetyl transferases p300, components of 
mSin3A/HDAC complex 52, AF10 53, and SIP/CoAA 54. Most of these interactions occur 
within or close to the N-terminal SNH domain. Some of these interactions share competitive 
overlapping binding sequences (Figure 2). 
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Figure 2. Domain structure of SS18 and protein-protein interaction sites 
SSX 
The SSX family of Cancer-Testis Antigens (CTAs) is comprised by 9 highly homologous 
members, which have been named sequentially based on their discovery as SSX1-9. SSX 
genes are localised on chromosome X and have their expression restricted to spermatogonia 
in testis 55 and fetal mesenchymal stem cells. SSX expression is down-regulated following 
mesenchymal stem cell differentiation, suggesting that SSX plays a role in the repression of 
cell differentiation 56 57. Although SSX genes are aberrantly expressed in vast human tumor 
types, no clear correlation between SSX expression and tumor prognosis has been found 
except for very few reports which show that the expression of SSX in late stage tumors is 
higher compared to early stage tumors 58. Studies have reported that SSX increases the 
invasive potential and represses E-cadherin expression in melanoma 57 and breast cancer cells 
59.  
Most of the SSX proteins consist of 188 amino acids 27 and contain three functional domains. 
The N–terminal Krüppel–associated box (KRAB) domain and the highly conserved C–
terminal dominant repressor domain (SSXRD) are the major domains 50,60. They can directly 
bind to DNA and show strong repressive effect. The SSX proteins are strong transcriptional 
repressors due to the activities of KRAB and SSXRD domain. Some studies suggest that the 
KRAB domain enhances the activity of the C-terminal SSXRD domain instead of showing 
intrinsic activity of its own 23, which suggests that the SSX mediated repression of gene 
regulation is mostly related with the activity of the SSXRD domain. A third functional 
domain of SSX refers to SSX divergent domain (SSXDD). Little is known about the function 
of SSXDD 61.  
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Proteins, such as RAB3IP (RAB3 interacting protein) and SSX2IP (SSX2 interacting protein) 
62, interact with SSX mainly within the KRAB domain. Although the KRAB domain is 
considered as the main functional domain, lots of protein-protein interactions occur outside of 
this region. For instance, there are several proteins that compose polycomb chromatin 
remodelling complex (PcG complex) colocalise with SSX through interacting with SSXRD 
domain, including BMI1 (B cell-specific moloney murine leukaemia virus insertion site 1 
protein), HPC2 (human polycomb group protein 2), RING1 (ring finger protein 1) and 
RING2. The transcription activator LHX4 was also found to be colocalised with SSX in this 
region 63 (Figure 3). 
Figure 3. Domain structure of SSX and protein-protein interaction sites 
1.2.1 SS18-SSX and transcriptional repression 
In the SS18-SSX fusion protein, the last 8 amino acids of SS18 (N-terminal) is replaced by 
78 C-terminal residues of SSX containing the repressor domain. The resulting chimeric 
protein contains both transcriptional activating and repressing domain (Figure 4). Hence the 
fusion protein harvests oncogenetic activities that are independent of the wild type SS18 and 
SSX proteins. It recruits new interacting partners that involve in gene transcription 
modulation and epigenetic regulation, such as transducer-like enhancer of split (TLE1), 
activating transcription factor 2 (ATF2), histone deacetylases (HDACs) and polycomb group 
members (PcG) 64.  
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Figure 4. Chromosome translocation t(x;18)(p11.2;q11.2) and aberrantly transcribed 
fusion gene SS18-SSX in synovial sarcoma. 
The transcription factor ATF2 carries a DNA-binding domain that promotes the transcription 
by recognising the cyclic AMP-response element (CRE) and recruiting histone 
acetyltransferases (HATs) 65. TLE genes are transcriptional corepressors, they interact with 
transcriptional activators and function negatively to inhibit the transcription of target genes 66. 
TLE1 involves in Wnt/β-catenin signaling pathway and is expressed during embryogenesis 
similar to other 3 TLE genes. Knösel et al. have reported that the TLE1 gene is overexpressed 
in 96% of the SS (249 out of 259 SS specimens) 67. Positive immunohistochemical staining of 
TLE1 is a strong indication of SS. Therefore TLE1 has been recognised as an excellent 
diagnosis marker for SS. However, some studies indicate limited specificity of TLE1 
expression in SS. Kosemehmetoghu et al. found positive TLE1 expression in 37% of the 
tested non-SS mesenchymal tumours68,69. 
With the assistance of these master transcriptional regulators, the fusion oncoprotein SS18-
SSX functions predominantly in transcriptional regulation in spite of lacking apparent DNA 
binding motif 70-72. Le Su et al. have reported that SS18-SSX forms a functional endogenous 
complex with recruited ATF2 and TLE1, which leads to the repression of ATF2 target genes 
and abnormal transcriptional activities that drive the malignant transformation in SS. The 
recruitment of ATF2 and TLE1 are independent processes and involve different protein 
domains of SS18-SSX. The oncoprotein SS18-SSX serves like a scaffold to link these 
proteins together 64. 
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The tumor suppressor early growth response 1 gene (EGR1) is an identified target of SS18-
SSX in SS. The fusion protein complex (more specifically, polycomb proteins) directly binds 
to the EGR1 promoter and results in the down regulation of the EGR1 expression 73,74. It has 
been reported that reintroduction of EGR1 in human tumor impairs tumor development and 
induces the expression of some tumor suppressors located downstream, like p53, 
transforming growth factor-β, phosphatase and tensin homolog (PTEN) and others. Small 
molecules that can reactivate EGR1 expression in SS cells such as romidepsin have been 
studied to find a way to reverse the transcriptional repression effect of the fusion oncogene 74. 
More molecules that are involved in the SS18-SSX-mediated transcriptional repression have 
been identified, including polycomb group complexes, trimethylated histone H3 lysine 27 
(H3K27me3) 75, enhancer of zeste 2 (EZH2), histone deacetylase 1 (HDAC1) , embryonic 
ectoderm development (EED) protein, suppressor of zeste 12 homolog (SUZ12) and insulin-
like growth factor 2 (IGF2) [31]. These molecules are recruited to the target 74promoters of 
the fusion protein SS18-SSX independently 64. Immunohistochemical examine of SS tissues 
has confirmed the expression of cyclin D1, β-catenin, cytokeratin, vimentin, BCL2, IGF-1R 
and KIT [32-34].  
1.2.2 SS18-SSX and p53 function 
The human TP53 gene is located on chromosome 17 and encodes one of the mostly studied 
tumor suppressor proteins, p53, which is also called the guardian of the genome. The 
activation of p53 happens in response to various cellular stresses such as DNA damage, 
oxidative stress and osmotic shock 76. Activated p53 shows a great anti-cancer character by 
holding the cell cycle at the G1/S stage through its downstream targets, activating DNA 
repair proteins, or initiating apoptosis when there are irreparable DNA damages. However, as 
the most frequently mutated gene in human cancer, TP53 mutations were identified in almost 
all types of cancer at rates of 10-100% 77 78. This indicates that point mutations induced 
disruption of p53-mediated tumor surveillance is a common strategy in tumourigenesis. 
SS cells carry intact copies of wild type TP53 genes and they fail to activate p53 functions in 
response to cellular stress such as DNA damage and deregulated oncogene expression. Gene 
expression profile studies of SS cells show that the inhibition of the SS18-SSX fusion gene 
reactivates p53 checkpoint pathway and induces growth arrest or apoptosis 79,80. Our group 
explained this observation by demonstrating that the SS18-SSX oncoprotein promotes TP53 
ubiquitination and degradation through a mechanism involving HDM2 (human double 
minute 2 homolog). In healthy cells, p53 is kept in a low level because of the p53-HDM2 
auto-regulatory loop, in which HDM2 acts as a negative regulator to promote the 
ubiquitination and degradation of p53 and prevents the aberrant activation. Ubiquitinized p53 
can be rapidly stabilised to maintain the genome stability when the cell senses cellular stress. 
However, in SS, the fusion protein SS18-SSX sustains HDM2 expression and promotes 
HDM2 stabilisation by inhibiting its auto-ubiquitination 81. In our study, we confirmed that 
HDM2 has an effect on p53 in a SS cell line that carries the SS18-SSX2 fusion gene. 
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Exposure of SYO-1 cells to the HDM2 antagonist nutlin-3 increases p53 stability, activates 
the expression of p53 target genes, thereby inducing growth arrest and apoptosis 82. 
1.2.3 SS18-SSX and Wnt/β-catenin signaling 
Studies have demonstrated that the Wnt/β-catenin signaling pathway is frequently activated 
in SS, indicating a unique function of the Wnt/β-catenin pathway in this cancer type 83. β-
catenin is a downstream target of the SS18-SSX fusion protein as well as an important 
component of the Wnt/β-catenin signaling pathway; The interference of β-catenin-mediated 
signaling results in the initiation of different types of tumours 84. Tadashi H et al. have 
observed that β-catenin is accumulated in the nuclei of primary and metastatic SS 85. The 
nuclear accumulation of β-catenin is important in maintaining the morphology of spindle 
cells in SS 83. It was further shown that nuclear accumulation of β-catenin promotes tumor 
progression and leads to short term survival of SS patients 85. By screening genetic alterations 
in series of 49 SS samples, it was found that 30-60% of SS cases contain mutations both in 
adenomatous polyposis coli (APC) and β-catenin 86.  
Functional evidence for a critical role of Wnt/β-catenin signaling in SS has been recently 
shown. Using SS tumor xenograft and a SS18-SSX2 transgenic mouse model, Whitney B et 
al. have found that the Wnt/β-catenin pathway is activated by the fusion oncoprotein SS18-
SSX2, which is reflected by the upregulation of Wnt/β-catenin cascade. This finding was 
confirmed in further studies that detected downstream targets of Wnt/β-catenin using 
immunohistochemistry staining in a cohort of 30 primary SS biopsies; Transfection of SS18-
SSX into HEK293 cells shows a similar activating function. The inhibition of Wnt/β-catenin 
signaling by knocking out of β-catenin prevents SS cell proliferation and tumour formation 
87.  
1.3 EPIGENETICS 
Epigenetics is the study of inheritable changes in gene expression that does not affect the 
DNA sequence. It is the study of phenotypical but not of genotypical changes. Histone 
modification, together with DNA methylation and non-coding RNA-associated gene 
silencing, initiate and sustain epigenetic changes. Compared with transcriptional regulation, 
epigenetic modulation is a fast reaction and takes place after proteins are synthesised, which 
allows the cell to respond fast to environmental changes.  
1.3.1 Histones, the core proteins of the nucleosome 
Each human diploid cell accommodates about 6 billion base pairs (bp) of DNA within 23 
pairs of chromosomes. The length of 1 bp DNA is about 0.34 nm, which means that there are 
approximately 2 metres of DNA in a single cell 88. Eukaryotic chromatins are highly efficient 
structures that compact such long DNA sequences to fit in the nucleus of the relatively small 
cell.  
The basic chromatin structure, a nucleosome, is the primary level of DNA compaction. It 
consists of 146 bp of the DNA that is on average tightly wrapped 1.65 times around a histone 
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octamer, like thread wrapped around a spool. Histones can tightly bind with DNA due to the 
negatively charged phosphate-sugar backbone of DNA. The histone octamer consists of a 
(H3-H4)2 tetramer and two H2A-H2B dimers 89. The linker histone H1 is located close to the 
DNA entry and exit region in a nucleosome unit. Strings of nucleosomes are further coiled 
into even shorter and thinner structures, which are called 30-nanometre fibres (Figure 5).  
The nucleosomal structures of eukaryotic chromatin form a physical barrier to the enzymes 
that unwind and copy DNA. DNA replication and gene transcription can therefore not happen 
since such processes require unwound DNA strands to allow polymerases access to the DNA 
template. Remodelling of highly compacted chromatin and modification of histones are 
temporarily reversible processes that control the accessibility of DNA. Once one or both of 
these processes are completed, the remodelled chromatin or modified histone returns to its 
compact state to keep the stability of the genome 90,91. 
 
          
Figure 5. Chromosome structure 
1.3.2 Histone modification 
A histone protein is constructed by a structured core and an exposed tail domain. The histone 
tail comprises more than 25% of the mass of a single histone. It protrudes from the histone 
core and provides an accessible surface for potential reactions with other proteins. Most of 
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the histone modifications occur on the amino acid residues in its tail in the form of 
methylation, phosphorylation, acetylation, ubiquitylation and sumoylation 92.  
Histone modification can help to partition the genome into distinct domains such as 
euchromatin that is under active transcriptions and heterochromatin that is inaccessible for 
transcription. Histone modification can facilitate DNA-based functions like DNA-replication, 
DNA repair and chromosome condensation. Histone acetylation and deacetylation are the 
most studied histone modifications and are reversible mechanisms. Histone acetylation 
depends on the activity of histone acetyltransferases (HATs), which move the acetyl groups 
onto lysine residues. Histone deacetylation depends on the activity of histone deacetylases 
(HDACs), which take the acetyl groups away (Figure 6). This post-translational modification 
can happen on any of the core histone components (H2A, H2B, H3 and H4) in a histone 
octamer, but is most common on H3 and H4. The marks of H3 that are most acetylated are 
lysine 9, 14, 18, 23 and 56 in most species. The acetylation of H4 normally takes place at 
lysine 5, 8, 12 and 16 93. Generally, the acetylation of certain lysine residues in the histone tail 
is associated with gene activation whereas the deacetylation is associated with a repressed 
gene expression. The balance between acetylation and deacetylation is crucial for the 
development of healthy cells.  
Histone acetyltransferases (HATs) 
There are 2 types of HATs according to their cellular localisation and biological function. 
Type A HATs acetylate nuclear histones that are closely related to gene transcription. While, 
type B HATs are often found to acetylate newly synthesised histones in the cytoplasm until 
they are transferred into the nucleus and bind to freshly constituted DNA sequence. More 
than 20 HATs have been identified, such as type A HATs Gcn5p and SAGA, which were 
discovered in yeast and target on H3 and nuclear H2B; p300, a human type A HATs that 
targets all the core histones; Hat1p, a yeast type B HATs that targets free H4 94. The human 
proteins that show HATs activities are classified as lysine (K) acetyltransferases (KATs) 95. 
Histone deacetylases (HDACs) 
The removal of acetyl groups from histones is accomplished by histone deacetylases 
(HDACs). So far there have been 18 mammalian HDACs identified 96. These isoforms can be 
further divided into 4 distinct classes according to their localisation, number of catalytic 
pockets and size. Class I HDACs include the enzymes HDAC 1, 2, 3 and 8, which primarily 
localise in the nucleus. The members of class II HDACs (HDAC 4, 6, 7, 9, 10) are believed 
to be able to deacetylate both non-histone as well as histone proteins according to their 
subcellular localisation between nucleus and cytoplasm. Both class I and class II HDACs are 
zinc-dependent and can be inhibited by the drug trichostatin A. The class IV HDACs, which 
contain only one isoform, HDAC11, has features of both class I and II. Interestingly, the class 
III HDACs is a group consisting of unique types of enzymes that are underlined by a special 
mechanism. Different from the Zn2+-dependent activity of other classes, these enzymes 
require NAD+ (oxidised nicotinamide adenine dinucleotide) as a cofactor and are not 
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sensitive to compounds that inhibit Zn2+ dependent enzymes. Class III HDACs are known as 
sirtuins (SIRT1-7) and are homologous with the yeast silent information regulator 2 (Sir2).  
HDACs regulate not only histones, but also a wide range of non-histone proteins. These 
substrates are key elements of crucial cellular processes. HDACs are therefore involved in 
numerous signaling pathways and play a pivotal role in chromatin remodelling and epigenetic 
regulation of gene expression. Abnormal expression of HDACs and related aberrant 
chromatin deacetylation displays significant effects on cell cycle and cell survival and 
contributes in oncogenesis. For example, it was reported that the expression of HDAC1 was 
upregulated in prostate, colon, gastric and breast carcinomas 97 98 99 100. Overexpression of 
HDAC 2, 3 and 6 were observed in different cancer specimens as well 101,102. Our previous 
study showed that some members of the class III HDACs, namely sirtuins, were 
overexpressed in SS 103. The hypoacetylation of lysine 16 on H4 was described as a hall mark 
of cancer 3. Studies also demonstrated that histone hypoacetylation is related with tumor 
invasion and metastasis 104. Different from DNA mutation, epigenetic modifications are 
reversible. This provides a possible strategy for the treatment of cancer by reversing the 
distorted epigenome to a normal epigenome in the affected cells. HDACs have therefore 
become interesting potential targets for cancer treatment.  
 
Figure 6. Histone acetyltransferases (HDIs) and deacetylases (HDACs) 
1.4 CLASS III HDACS: SIRTUINS 
Sirtuins are a group of phylogenetically conserved proteins that have been found in archaea, 
bacteria, eukaryote and even viruses 105. It was first discovered as a transcriptional repressor 
of the mating type yeast, named as Silent Information Regulator 2 (SIR2). In the late 1990s, 
several studies showed that deletion of SIR2 shortens the lifespan of Saccharomyces 
cerevisiae, while increased SIR2 gene dosage extends its lifespan 106. Similar effects were 
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observed subsequently in Caenorhabditis elegans and Drosophila melanogaster 107,108. These 
findings triggered great interest for finding similar effects in mammals and in particularly 
humans.  
Since 1999, seven mammalian sirtuin paralogues (SIRT1-7) have been identified 109. They 
share a highly conserved catalytic and binding domain (also called sirtuin corn domain), 
which consists of a typical Rossmann fold and a small zinc-binding domain composed by 
approximately 250 amino acids. The structures of amino- and carboxy-terminal extensions of 
the 7 mammalian sirtuins are quite divergent, which may endow them diverse biological 
functions, distinct subcellular localisations, special enzymatic activities and various unique 
substrates during evolution.  
SIRT1 and SIRT6 are found predominantly in the nucleus, SIRT3, 4 and 5 are localised in the 
mitochondria, whereas SIRT2 primarily resides in the cytosol and SIRT7 in the nucleolus. 
Sometimes SIRT1 and SIRT2 can be observed both in the nucleus and cytoplasm which 
suggests that they shuttle between different compartments within the cell 110. The subcellular 
localisation of mammalian sirtuins is probably also dependent on cell type, stress status and 
molecular interactions. SIRT1 and SIRT2 are the most studied mammalian sirtuins 109. 
Table 2. Mammalian sirtuins’ properties 
Mammalian sirtuins Cellular localisation Enzymatic activities 
SIRT1 Nucleus Deacetylase 
Cytoplasm Deacetylase 
SIRT2 Cytoplasm Deacetylase 
Nucleus Deacetylase 
SIRT3 Mitochondia Deacetylase 
Cytoplasm Deacetylase 
SIRT4 Mitochondia ADP-ribosyl-transferase 
SIRT5 Mitochondia Deacetylase, Deacylase 
SIRT6 Nucleus Deacetylase, ADP-ribosyl-transferase 
 
SIRT7 
Nucleolus Deacetylase 
Cytoplasm Deacetylase 
1.4.1 Sirtuin substrates and activities 
Sirtuins harbour 2 types of different but related enzymatic activities: deacetylase activity and 
ADP-ribosal transferase activity as described in Hawse and Du J’s papers 111 112. However, 
the current understanding of the latter is very limited.  
Histones are the most conserved and basic substrates of the sirtuin family. Sirtuins transfer 
acetyl groups from certain substrates to an ADP-ribose molecule in assistance of NAD+, 
which is a key factor involved in the cellular metabolism. Sirtuins’ activities are strongly 
dependent on the availability of cellular NAD+.  
Sirtuins act as sensors of the balance between metabolism and energy and thereby 
coordinates cellular maintenance of the genome integrity 113,114. In the past decade, a lot of 
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research has been done to investigate the correlations between sirtuins and metabolic 
pathways. Sirtuins, especially SIRT1, are involved in cellular metabolism regulation under 
the condition of calorie restriction (CR). Numerous studies have shown that in many 
organisms, like yeast, worms, mice and flies, CR prolongs the lifespan up to 50%. NAD+ 
levels are also observed to be increased as well as upregulated SIRT1 expression in some 
tissues during CR 115.  
Sirtuins target histones and a wide range of non-histone substrates. Many of these substrates 
are important enzymes that are involved in different biological pathways and cellular 
functions that regulate the stress response, chromatin machinery, transcription, genome 
stability, metabolism, etc. Examples include the chromatin related protein p300; stress related 
proteins p53, FOXO1, HIF1a; DNA repair protein Ku70; metabolic components ACS1, 
ALDH2, GDH 116,117. By regulating the activity of various substrates, sirtuins are involved in 
many human diseases, especially age-related diseases such as cancer, diabetes and 
cardiovascular disease. Despite the diversity of sirtuin substrates, Gil Blander and his 
colleagues showed in their study that substrate recognition of SIRT1 does not depend on the 
amino acid sequence close to the acetylated lysine 118. Instead, sirtuins preferentially 
deacetylate acetyl-lysine within unstructured regions, which suggests that conformational 
requirement might be a general feature of substrate recognition in the sirtuin family 119. 
In animal models, the transgenic SIRT6 mouse exhibits a 10-15% increased lifespan 
compared with their wild-type littermates 120. However, the normal human cells that are 
studied show no sign of prolonged lifespan when the expression of a single sirtuin protein is 
increased 121. Several reports indicate that deregulated expression of sirtuins is involved in the 
development of various malignancies 122. Apart from SIRT1 and SIRT2, the molecular 
mechanisms underlying sirtuin-mediated biological functions and the particular pathways 
remain poorly understood. 
1.4.2 The oncogenic role of SIRT1 and SIRT2 
Cancer is such an incredibly heterogeneous disease for which every single sample is unique. 
Even in several specimens of the same tumour, the mutated genes are widely diverse. For 
most cancer related genes, including sirtuins, it is not easy to simply classify them into either 
tumor prompters or tumor suppressors. Multiple issues have to be considered, such as the 
type of cancer, the stage of its development, tissue of origin, experimental conditions. The 
most investigated members in the sirtuin family for their role in regulation of cancer 
metabolism are SIRT1 and SIRT2, which are also the main study targets of two constituent 
papers of this thesis. 
SIRT1 
With the extraordinary boost of interest in investigating sirtuins during the past decade, the 
list of sirtuin targets were rapidly identified and extended and their cellular functions became 
better understood. Evidence suggests that SIRT1 plays a dual role in different types of cancer. 
Initially, most of the studies suggest that SIRT1 acts as a tumor promoter because of its 
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overexpression in breast cancer, colon cancer, leukaemia, prostate cancers, etc. compared to 
the corresponding normal tissues. Inhibition or down regulation of SIRT1 with siRNA 
impairs tumor cell proliferation 123. The first identified substrate of SIRT1 was the tumour 
suppressor p53. SIRT1 deacetylates lysine 382 of p53 and therefore inhibits its activity, 
allowing tumor cells to bypass p53-mediated apoptosis, resulting in a higher risk of 
accumulating mutations and developing cancer 124. Some in vivo studies carried out by 
Herranz et al. demonstrated that the crossing of SIRT1 transgenic mice to PTEN deficient 
mice leads to SIRT1 overexpressed offsprings that are prone to develop thyroid carcinoma 
and lung metastasis. These mice also show a much higher incidence of developing prostate 
cancer, which is in agreement with SIRT1 levels being higher in murine and human prostate 
carcinomas 125. It has been reported that gain of SIRT1 expression by siRNA transfection 
decreases the sensitivity of some cancer cells to certain anti-cancer compounds. Similarly, 
loss of SIRT1 activity leads to opposite effects on apoptosis and chemosensitivity 126. 
Moreover, SIRT1 inhibits the FOXO- and P53- related apoptosis or transcription through its 
deacetylase activity 127. All together, these studies suggest that overexpression of SIRT1 
plays a direct role in promoting tumourigenesis. 
However, there are numerous contradictory findings about the role of SIRT1 in cancer. For 
instance, SIRT1 expression is significantly reduced in certain cancer types, including bladder 
carcinoma, breast cancer, glioblastoma, ovarian cancer and hepatic carcinoma, relative to 
their non-transformed counterparts. Reactivation of SIRT1 in these tumors leads to impaired 
cell proliferation 128. BRCA1-mutated human breast cancer has a lower SIRT1 level 
compared to non-BRCA1-related breast cancer and normal breast tissue. Activation of SIRT1 
by resveratrol in BRCA1 cancer cells leads to decreased cell viability 129. Yuan et al. have 
found several c-MYC binding sites at SIRT1 promoter region. The over expression of c-
MYC leads to upregulated SIRT1 expression130. However, SIRT1 negatively regulates c-
MYC stability through deacetylating the lysine 323 of c-MYC, resulting in decreased c-MYC 
downstream gene expression, such as telomerase reverse transcriptase gene (TERT), and 
enhanced expression of tumor suppressors like p21 130. These findings indicate a tumor 
suppressor role of SIRT1.  
SIRT2 
Analogous with the dual role of SIRT1 in cancer, SIRT2 also shows both tumor promoting 
and suppressing activity in different cancer types. Danielle et al. have found that SIRT2 
expression is greatly upregulated in melanomas compared to in normal melanocytes 131. 
Hiratsuka et al. have reported that SIRT2 gene was down-regulated in human glioma, where a 
colony formation assay showed that the abnormal expression of SIRT2 in glioma cells leads 
to significant reduction of stable clones 132. Mechanistical studies aiming to understand the 
functions of SIRT2 have been performed. Hyun-Seok Kim et al. knocked out SIRT2 gene in 
mice and observed higher level of mitotic regulators and mitotic cell death. As a 
consequence, the SIRT2 deficient mice showed a greater chance to develop tumours in 
various organs 133. These results indicate a tumour suppressor role of SIRT2 in certain cancer 
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types. Nevertheless, several studies have provided convincing evidences that SIRT2 promotes 
oncogenic phenotypes. Dan et al. reported significant SIRT2 upregulation in primary acute 
myeloid leukaemia (AML) cells in comparison to normal bone marrow cells. Inhibition of 
SIRT2 results in impaired cell proliferation and increased apoptosis in both AML cell lines 
and primary cells 134. In the same manner, upregulated SIRT2 in neuroblastoma and 
pancreatic cancer cells stabilises the Myc oncoprotein through repressing Myc ubiquitination 
and degradation resulting in promotion of cancer cell growth 135.  
The debates about whether SIRT1 and SIRT2 are tumour promoters or suppressors have not 
been solved to date. All the data so far suggest that both SIRT1 and SIRT2 play a dual role in 
different cancers, which is not unprecedented. For instance, the expression of TERT 
significantly increases tumor cell adhesion and migration 136. TERT induced telomere 
dysfunction decreases genomic stability; this indicates a tumourigenesis promoter function of 
TERT. However, it has also been shown that telomere dysfunction could be recognised by 
DNA damage machinery and hence activates tumour suppressor pathways 137. The genomic 
hypomethylation by Dnmt1 (DNA methyltransferase 1) promotes tumor initiation by 
destabilising the genome and silencing tumor suppressor genes, yet the Dnmt1-induced DNA 
hypomethylation might also reduce the risk for cancer as shown in the study of the Dnmt1 
transgenic mouse model 138. Similar with those genes, the specific activity of SIRT1 and 
SIRT2 in tumour development may correspondent with certain cellular and molecular 
context, and specific tumour microenvironment. Further studies of the functions of sirtuins 
should take these factors into consideration. A better understanding of the activities and 
functional roles of sirtuins will be beneficial for the further investigations of sirtuins as 
therapeutic targets. 
 
1.5 HDAC INHIBITORS 
1.5.1 Class I, II and IV HDIs 
There are many natural and synthetic compounds have been identified as class I, II and IV 
HDAC inhibitors (HDIs). They are categorized into different groups according to their 
different chemical nature, mechanism of action and heterogeneous biochemical structure. 
However, all of the Zn2+ dependent HDIs share three pharmacophoric groups. They contain 
an aromatic cap, which is also a surface recognition unit, a functional Zn2+ binding domain 
that can chelate the cation at the bottom of the HDAC catalytic pocket, and a hydrophobic 
linker that connects the top hat and the bottom part. Modifications on any of the groups will 
affect the potency and activity of the inhibitor (Figure 7). 
For example, TSA (trichostatin A) is a representative HDI that belongs to the group of 
hydroxamic acid. It is one of the first HDAC inhibitors that has been described and well 
studied. The disadvantage of TSA is its unspecific HDAC targeting and strong toxicity. 
However, the structure of TSA provides lots of inspiration for developing synthetic drugs that 
are less toxic and more specific. An example of this is suberoylanilide hydroxamic 
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acid (SAHA) 139, also called vorinostat, the earliest HDI that has been approved by the U.S. 
Food and Drug Administration (FDA) for use in cutaneous T cell lymphoma treatment. Other 
chemicals belonging to this group like LBH589 (panobinostat), PXD101 (belinostat), SB939 
(pracinostat) have also been evaluated in clinical trials for different types of cancer 140 141 142. 
Hydroxamic acids are the most studied HDIs. 
 
Figure 7. Hydroxamic acids as HDAC inhibitors 
Short chain fatty acid is a novel class of HDIs that includes valproic, 4-phenylbutanoic and 
butanoic acid. Valproic acid is a very old drug that has been previously used to treat epilepsy. 
Studies have shown that valproic acid induces the differentiation and/or apoptosis of 
carcinoma cells and patient-derived myeloid leukaemic blasts in vitro. It also suppresses 
tumor proliferation and metastasis in vivo 143,144. Similarly, 4-phenylbutyric acid is a drug that 
has been approved for the treatment of urea cycle disorders, but has recently been 
repositioned as an anti-cancer drug. The activity of 4-phenylbutyric acid has been studied in 
malignant glioma and acute myeloid leukaemia 145. In a clinical trial, the response was 
observed in a patient with metastatic non-small cell lung cancer treated with butanoic acid 146.  
1.5.2 Sirtuin inhibitors  
Because of the complexity and dual roles that SIRT1 and SIRT2 play in cancer, small 
molecules that target sirtuins were considered to have potential therapeutic benefit for cancer 
patients. Sirtuin activators that have been developed were mainly targeting SIRT1. There are 
more than 3000 SIRT1-activating compounds that have been synthesised and studied since 
the last decade, including SRT1720, SRT2183, SRT2104 147 148, and some analogs of 
nicotinamide (NAM) 149 150, most of them were used for the treatments of ageing and age-
related diseases like diabetes, cardiovascular disease and certain cancer types 151. However, in 
cancer field, studies are more focused on the development of sirtuin inhibitors. 
Nicotinamide (NAM) 
Aromatic cap
Hydrophobic 
linker
Zn2+ chelating group
Hydroxamic acids
Trichostatin A (TSA) Vorinostat (SAHA)
Panobinostat (LBH589) Pracinostat (SB939)
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NAM is one of the first sirtuin inhibitors and the only physiological sirtuin inhibitor that has 
been found 152. Benzamide is a sirtuin inhibitor that has a very similar structure with NAM 153 
(Figure 8). Analogs of NAM and benzamide have been studied. The anti-cancer activities of 
these compounds have been observed in human leukaemia, colon cancer 154, prostate cancer 
155, oral cancer 156, etc.  
 
Figure 8. Chemical structure of 3 sirtuin inhibitors. 
Thioacyllysine-containing compounds 
The first thioacyllysine-containing compound was synthesised by incorporating a N-
thioacetyllysine into a peptide that is derived from the 372-389 amino acid residue region of 
human p53. The mechanism of the action of this molecule has been studied extensively. It 
can form a strong stable covalent intermediate with sirtuins and sirtuin-targets at early stages 
of the deacetylation, therefore the active site of the sirtuin is occupied and the deacetylation 
reaction can not be processed 157,158. The earliest thioacyllysine-containing compounds are 
peptide-based. The potency and specificity of these peptides have been tested intensively and 
the IC50 of the most potent SIRT1 inhibitor was 0.2 µM 159. However, the disadvantages of 
peptide-based inhibitors are that they are not so stable and have poor cellular permeability, 
which represents a problem for in vitro studies. Therefore, efforts were made to replace the 
peptides with pseudopeptides in thioacyllysine-containing compounds. Mellini and 
colleagues developed thioacetylated pseudopeptides with in vitro activity against SIRT1-3 in 
multiple cancer cells 160. 
Indole derivatives 
A group of indole derivatives represented by EX527 were discovered as potent sirtuin 
inhibitors 161. Solomon J et al. have shown that EX527 inhibits the catalytic activity of SIRT1 
and increased the acetylation of p53 in several types of cancer 162. Other members of this 
group, such as AC-93253 and inauhzin, also show cytotoxic activities on multiple cancer 
types, like prostate cancer, pancreatic cancer and leukaemia 163,164. 
Tenovin and its analogs 
Tenovins, including tenovin-1 and tenovin-6, is a group of bioactive molecules discovered by 
their ability to re-activate the function of the tumor suppressor p53. Tenovin-6 inhibits SIRT1 
Nicotinamide (NAM) Benzamide 2-Anilinobenzamide
N
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mediated deacetylation of lysine 382 of P53 in cancer cells 165, and restores p53-mediated 
DNA repair or apoptotic function. The cytotoxic effect of tenovin-1 has been shown in 
melanoma, lymphoma and breast cancer cells in vitro. Tumours with wild type p53 show 
better response upon tenovin-1 treatment compared to the ones that carry mutant p53 165. 
Tenovin-6 is water soluble and more active in impairing tumor growth compared to its 
analogue tenovin-1166. The cytotoxic activity of tenovin-6 has been reported for many cancer 
types, like uveal melanoma, acute lymphoblastic leukaemia, SS, RMS, gastric cancer and 
cutaneous T-cell lymphoma 103,167 168 169,170.  
Other sirutin inhibitors 
AGK2  
AGK2 doesn’t belong to any of the groups mentioned above. It was discovered as a potent 
SIRT2 inhibitor that shows protective activity against Parkinson's disease both in vitro and in 
vivo 171. AGK2 induces apoptosis and necrosis in C6 glioma cells in vitro 172 and it is the 
most selective SIRT2 inhibitor to this date 173.  
Sirtinol and its analogues 
The SIRT2 inhibitor Sirtinol was identified from a cell-based high throughput drug screening. 
Sirtinol and its analogues inhibit cancer cell proliferation and induce p53-mediated apoptosis 
174. Salermide and cambinol are SIRT1 and SIRT2 inhibitors that have been developed based 
on the structure of sirtinol. The anti-proliferative activities of these 2 groups of molecules 
have been reported in cancer cells 175. 
Despite the discovery of a big amount of pharmacological sirtuin modulators, they are in 
general not specific and potent enough due to the complexity of the sirtuin activities. 
Moreover, most of them only target on SIRT1 and SIRT2. Studies that focus on other 
mammalian sirtuins are very limited. Further research is therefore crucial to improve the 
understanding of individual sirtuin functions and the development of more specific sirtuin 
inhibitiors. 
1.6 TREATMENT STRATEGIES FOR SS   
SS is a rare and aggressive tumor. There is no consensus among different oncological centres 
for what is the best standard treatment for SS. The primary treatment normally involves 
complete surgical resection of the tumor and adjuvant radiotherapy before or after surgery. 
However, the recurrence is very common and more than 50% of the patients develop 
metastases. The 5-year overall survival rate for the patients with local recurrence and 
metastatic disease is 76% and 10%, respectively 176. 74-81% of metastatic diseases occur in 
the lungs and approximately 20% in lymph nodes and bones 177. Similar to the primary SS, 
surgical resection is the main approach to treat local recurrence. For metastatic SS, the routine 
use of chemotherapy has limited benefit due to the therapeutic toxicity and eventual 
progression of the disease 178. 
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Lots of efforts have been made for the purpose of developing new therapeutic options to 
improve SS outcomes. For example, immunotherapy againsts the cancer-testis antigens NY-
ESO-1 and SSX, two antigens expressed in sarcomas and other tumors but not in normal 
cells, have been considered as potential therapeutic options 179 24. FZD10 (frizzled homologue 
10), a cell surface receptor, is present in SS cells but not in normal tissue, and is a promising 
therapeutic target. Antibodies that recognise this protein have been tested in SS xenografts 
and showed encouraging results 180. 
The expression of the fusion protein SS18-SSX is unique in SS, the following composition of 
the oncoprotein complex leads to aberrant transcriptional activity and dysregulated gene 
expression which are necessary to initiate the tumourigenesis and sustain tumor cell survival. 
Direct targeting of the SS18-SSX complex is therefore an attractive approach for the 
discovery and development of molecules for SS treatment. Compounds that are able to 
dissociate the SS18-SSX complex or target constituent proteins of the complex might be 
beneficial for SS patients.  
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2 AIMS OF THE THESIS 
The general aim of the thesis was to look for a novel therapeutic target for synovial sarcoma. 
The work mainly focuses on investigating the biochemical activity between the constituent 
proteins in chimeric SS18-SSX complex and potential compounds that can disrupt the 
chimeric fusion protein. 
The specific aims of these studies were: 
Paper I: To investigate the role of sirtuins in the proliferation and survival of two paediatric 
soft tissue sarcomas: rhabdomyosarcoma and synovial sarcoma.  
Paper II: To set up a high-throughput screening assay to screen for small molecules that 
disrupt the association between SS18-SSX and TLE1 in synovial sarcoma by using proximity 
ligation assay (PLA). 
Paper III: To investigate the clinical relevance of the over-expressed SIRT1 and SIRT2 
proteins in a cohort of 30 primary synovial sarcomas and obtain insight into the epigenetic 
mechanisms associated with the action of sirtuin inhibitors in SS.  
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3 RESULTS AND DISCUSSION  
 
PAPER I 
SIRT1 and SIRT2 inhibition impairs paediatric soft tissue sarcoma growth 
Sirtuins are a class of conserved proteins that shows deacetylases or ADP-ribosyl transferases 
activities on histone and non-histone substrates. They are involved in numerous cellular 
processes including cellular metabolism, cell cycle, DNA integrity maintenance and 
tumourigenesis. SIRT1 and SIRT2, the most studied mammalian sirtuins, have been 
associated with different cancer processes, however, their role in cancer development is still 
controversial. 
In paper I we investigated the possible oncogenic roles of SIRT1 and SIRT2 in two paediatric 
sarcoma models: alveolar rhabdomyosarcoma and synovial sarcoma. 
We showed that SIRT1 was significantly upregulated in both SS biopsies and cell lines 
compared to normal mesenchymal cells. To investigate possible roles of SIRT1 and SIRT2 
on the proliferation of RMS and SS, we inhibited the activity of SIRT1 and SIRT2 with a 
sirtuin inhibitor, tenovin-6. We observed that tenovin-6 showed a fast and significant effect in 
impairing the sarcoma cells’ proliferative capacity but not in primary mesenchymal stem 
cells. By measuring the level of caspase 3/7, we found that the sarcoma cells appeared to 
undergo apoptosis only at high concentrations of tenovin-6.  
Tenovin-6 was discovered as a p53 activator. It reactivates p53 through inhibiting the 
deacetylation activities of sirtuins, which target the lysine 382 residue of p53. To investigate 
whether the activity of tenovin-6 in sarcoma cell lines was associated with p53 reactivation, 
we analysed the expression levels of acetylated k-382-p53 and p21. We found that in tenovin-6 
exposed cells, the expression of p21, a downstream target of p53, was upregulated with no 
changes in the overall expression of SIRT1, SIRT2 or p53. This upregulated expression of 
p21 is independent of the mutation status of the p53 gene. Interestingly, the enzymatic 
activity of sirtuins was however decreased in all of the cell lines investigated. This result 
indicates that the inhibition of the de-acetylating function of SIRT1/SIRT2 with tenovin-6 is 
p53 independent. 
The cytotoxic activity of tenovin-6 has been associated with dysregulated autophagy in 
melanoma cell lines. With this in mind, we assessed the autophagic flux in several sarcoma 
cell lines in the presence of tenovin-6 treatment. We found that tenovin-6 induced 
accumulation of LC3II and p62 in SS and RMS cell lines. This pointed to a connection of 
SIRT1 and autophagic flux and was subsequently confirmed by the accumulated 
autophagosomes in the treated cell lines using a tandem probe RFP-GFP-LC3, which can 
visualise the autophagosome and autolyosome with different colours in transfected cells. Our 
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investigations confirmed that the inhibition of sirtuins by tenovin-6 in sarcoma cells blocks 
the autophagy process and promotes cell death. 
Sirtuins are involved in the regulation of the cellular metabolism. Increased NAD+ levels and 
sirtuin activities were observed under the condition of calorie restriction.  In order to enquire 
into the activity of tenovin-6 in starving conditions, we cultured a SS cell line, SYO-1, and a 
RMS cell line, RD, in a nutrient-deprived medium which did not contain any glucose and 
essential amino-acids. We treated the cells with 2µM tenovin-6 and found that the anti-
tumour activity of tenovin-6 was increased in the nutrient-deprived condition in sarcoma cell 
lines. This result indicates that the activity of SIRT1 and SIRT2 is crucial for SS and RMS in 
the condition of nutrient deprivation, a condition observed in fast-growing tumors such as 
sarcomas.  
The pivotal role of SIRT1 and SIRT2 in tumor cell survival was confirmed using siRNA 
assays in the RMS cell line RD. We found that the proliferation of the tumour cells was 
impaired due to the siRNA silencing of SIRT1 and SIRT2. The cytotoxic effect was observed 
48 hours after transfection and increased gradually through out the 120 hrs of the assay 
during which the nutrient supply becomes deficient in the culture medium. Our result shows 
that the expression of SIRT1 and SIRT2 is crucial for the survival of SS and RMS cells.  
We further evaluated the activity of tenovin-6 in vivo. SCID mice were xenografted with the 
RMS cell line RD and treated with tenovin-6 at the time tumour xenografts were palpable. 
After 10 days of treatment with tenovin-6, we found decreased tumour volumes in tenovin-6 
treated mice compared to the placebo group. However at later times, tumour growth was 
evident in both tenovin-6 and placebo treated groups. This study shows that tenovin-6 has a 
weak anti-tumor effect in vivo, and suggests that drug combinations may enhance tenovin-6 
activity.  
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PAPER II 
Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions 
by proximity ligation assay 
Synovial sarcoma is one of the most studied translocation-associated sarcomas. In this tumor, 
the fusion protein SS18-SSX forms a functional complex with proteins that are involved in 
epigenetic regulation and chromatin remodelling to reprogramme gene transcription and drive 
malignant transformation in synovial sarcomas. The known component proteins in this 
complex include ATF2, TLE1, HDACs and polycomb group (PcG) members.  
Today there is no effective systemic treatment for patients with synovial sarcoma. We 
hypothesise that dissociating the SS18-SSX protein complex will specifically induce synovial 
sarcoma cell death. Therefore, small molecules that are capable to disrupt the protein-protein 
interactions within the oncoprotein complex may have selective anti-tumor activity in patients 
with synovial sarcoma.  
In order to develop a high-throughput drug screening assay to search for molecules that 
disrupt the SS18-SSX driver complex, we have set up a proximity ligation assay (PLA) to 
visualise the interaction of SS18-SSX with its partner TLE1 in synovial sarcoma cell lines.  
Using an antibody that recognise both wild type SS18 and the fusion protein SS18-SSX and a 
TLE1 specific antibody, we could detect specific SS18/TLE1 PLA signals in SS cell lines. 
On the contrary, the SS18-TLE1 proximity ligation signal was very weak or negative in the 
cell lines of other cancer types. This result was confirmed by co-immunoprecipitation, which 
further demonstrated that the PLA signals we detected in synovial sarcoma cell lines are due 
to the co-localisation of SS18-SSX with TLE1. 
To confirm the specificity of the PLA assay, we knocked down SS18-SSX with siRNA 
molecules and shRNA vectors that specifically target the SSX domain in the fusion transcript. 
PLA signals were clearly decreased in SS18-SSX silenced cells. We therefore concluded that 
the interaction of SS18 with TLE1 is specific for synovial sarcomas and involves only the N-
terminal SS18 part of the fusion protein, but not the wild type SS18.  
We also showed that the proximity ligation assay can detect the SS18-SSX and TLE1 
interactions in formalin-fixed paraffin embedded synovial sarcoma tumor samples.  
We next investigated whether the PLA could be used to screen for molecules that disrupt the 
SS18-SSX complex in synovial sarcoma. It has been previously shown that synovial 
sarcomas are very sensitive to class I HDAC inhibitors due to the dissociation of the SS18-
SSX/TLE1 complex. To investigate whether the disruption of the SS18-SSX/TLE1 complex 
is detectable using PLA, we treated the synovial sarcoma cell line SYO-1 with different 
HDAC inhibitors. The proximity ligation signals of the SS18-SSX/TLE1 complex were 
quantified and compared shortly after treatment. As expected, the class I HDAC inhibitor 
romidepsin (FK228) efficiently dissociated SS18-SSX molecule from TLE1 resulting in 
increased apoptosis, while other types of HDAC inhibitor didn’t. These results were further 
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confirmed by co-immunoprecipitation. Our results indicate that only class I HDAC inhibitors 
can disrupt the SS18-SSX/TLE1 fusion complex in synovial sarcomas. 
Having proved the utility of the PLA as a phenotypical assay to screen for molecules that 
disrupt the SS18-SSX TLE1 interaction, we then screened a library containing 16,000 
compounds (Maybridge) against the synovial sarcoma cell line SYO-1 and used PLA to find 
cytotoxic compounds that are capable to dissociate the SS18-SSX/TLE protein complex. One 
of the compounds, designated SXT1596, showed a particular anti-proliferative activity 
associated with complete loss of SS18-SSX/TLE proximity ligation signals and onset of 
apoptosis in the synovial sarcoma cell line SYO-1. 
The SS18-SSX/TLE1/ATF2 complex directly binds to the EGR1 promoter and represses its 
transcription. The compound SXT1596 reactivates EGR1 transcription in SS cells, indicating 
that disruption of the SS18-SSX complex releases the repression of EGR1 and restores 
normal signaling in synovial sarcoma. 
This study proves that the proximity ligation assay is a reliable and valuable method to screen 
for compounds that disrupt the fusion oncoprotein associations in SS. It also shows the 
possibility of using the proximity ligation assay to identify compounds with therapeutic 
potential in other cancer types that are driven by fusion transcription factors. 
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PAPER III  
Studies on the clinical relevance and mechanism of activity of sirtuin inhibitors in 
synovial sarcoma 
Sirtuins are class III HDACs that play important roles in a wide range of cellular processes 
like transcriptional gene silencing, DNA repair, cell cycle arrest, apoptosis and ageing. The 
most studied mammalian sirtuins, SIRT1 and SIRT2, were shown to have both tumour 
promoter and suppressor roles in cancer. Small molecules that target SIRT1 and SIRT2 were 
therefore considered to be beneficial for cancer patients, especially SIRT1 and SIRT2 
inhibitors. However, the mechanisms underlining most of the sirtuin inhibitors are still poorly 
understood. 
Dysregulated expression of both SIRT1 and SIRT2 were reported in different cancer types. In 
order to assess the expression of SIRT1 and SIRT2 in synovial sarcoma, we performed 
mRNA quantification of the both targets in a cohort consisting of 30 primary synovial 
sarcomas. We found a significant 10-fold increment of SIRT1 mRNA levels in 57% of the 
samples compared to the SIRT1 mRNA levels in normal cells.  
In order to further explore whether this overexpression is associated with clinical outcomes of 
the patients, we performed wilcoxon nonparametric tests based on our sample size. The 
clinical and molecular characteristics analysed include the patient’s gender, age, SSX type, 
tumour size and metastatic site(s). No significant correlation was found between these 
parameters and SIRT1/SIRT2 overexpression. This result may be explained by the small 
sample size and low statistical power of the experiment. Because synovial sarcoma is a very 
rare disease, the chances of obtaining patient material are very limited. The amount of our 
primary synovial sarcoma samples was quite small. For further and more accurate statistical 
analyses, a bigger collection of the tumour samples should be evaluated. 
Small molecules that are able to inhibit the activities of SIRT1 and SIRT2 have been 
developed and investigated as novel therapeutics for cancer. In this study, we evaluated 
tenovin-6 (an inhibitor of both SIRT1 and SIRT2) and AGK2 (a potent SIRT2 inhibitor) in 
different SS cell lines and a patient-derived primary SS culture 83SS that was established and 
characterized in our lab. We found that AGK2 inhibited the viability of SS cells at an IC50 
concentration of 5-6µM. Tenovin-6 on the other hand was more toxic than AGK2, it impaired 
the viability of SS cells at an IC50 concentration of 2.5µM. The cytotoxicity of both 
compounds was also demonstrated in real time proliferation curves of the SS cell lines SYO-
1 and 83SS. 
The fusion oncoprotein SS18-SSX recruits additional interacting partners that are involved in 
gene transcription and epigenetic regulation to form a functional complex. The SS18-SSX 
complex predominantly regulates gene transcription and tumour cell survival in synovial 
sarcomas. In our previous paper, we have demonstrated that synovial sarcoma was sensitive 
to class I HDAC inhibitors due to the disruption of the SS18-SSX/TLE1 fusion complex. 
However, there are still no studies that fully explain how the synovial sarcoma fusion 
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complex works and what the constituent proteins are. Based on the dysregulated expression 
and necessity of SIRT1 and SIRT2 in the survival of synovial sarcoma cells, we assumed that 
these two proteins are subunits of the SS18-SSX complex since the dissociations of SS18-
SSX/SIRT1 and SS18-SSX/SIRT2 by small molecular inhibitors are lethal for synovial 
sarcoma cells.  
In order to prove this, we performed co-immunoprecipitation in total cell extracts of synovial 
sarcomas. We found that the fusion protein SS18-SSX was pulled down with SIRT1 in 
synovial sarcoma cell line SYO-1 and the primary synovial sarcoma culture 83SS. Moreover, 
we found that H4K16ac and H3K9me3 were able to precipitate with SIRT1 as well. These 
results indicate that SIRT1, together with its histone targets H4K16ac and H3K9me3, share 
interactions with the fusion protein SS18-SSX in synovial sarcoma cells. Interestingly, a 
dissociation of the SS18-SSX/SIRT1 induced by 2µM tenovin-6 could already be observed 
after 2 hours of treatment, as well as the association between SIRT1 and 
H4K16ac/H3K9me3. However, H3K9me3 and H4K16ac gradually re-associated with SIRT1 
in the absence of the fusion protein. These results were further confirmed by PLA. 
To determine the mechanism of action of compound AGK2, we performed similar 
experiments. Protein-protein interactions of SS18-SSX/SIRT2, SIRT2/H3K9me3 and 
SIRT2/H4K16ac were observed in SYO-1. A concentration of 5µM AGK2 showed the 
activity of dissociation of these interactions in a time dependent manner. The effect of AGK2 
peaked at 8 hours of treatment and the interactions were completely disrupted at this time 
point.  
The results of this study are still preliminary, but indicate a possible role of SIRT1 and SIRT2 
in synovial sarcoma tumourigenesis that is driven by the SS18-SSX complex induced 
transcriptional dysregulation and epigenetic modulation. 
 
 
 
  
   41 
4 CONCLUSIONS  
 
Synovial sarcoma is a rare disease driven by the aberrantly expressed fusion oncoprotein 
SS18-SSX and the related fusion oncoprotein complex. In the first paper, the expression, 
activity and necessity of the NAD+ dependent class III HDACs, sirtuins, were examined with 
the focus on SIRT1 and SIRT2 in SS and RMS. We concluded from the study that: 
• SIRT1 and SIRT2 expression and activity are crucial for the survival of sarcoma cells.  
• The pharmacological inhibition of SIRT1 and SIRT2 by tenovin-6 impairs tumor cell 
proliferation, induces apoptosis and impairs the autophagy flux in sarcoma cells.  
The fusion protein SS18-SSX is unique and necessary for the survival of synovial sarcoma. It 
recruits interacting proteins and forms an endogenous fusion protein complex in SS cells that 
regulate gene transcriptions. Therefore, the fusion oncoprotein complex is a potential 
therapeutic target in synovial sarcoma.  Small molecular compounds that are capable to 
disrupt the fusion protein complex may have selective anti-tumor activity. TLE1 is a known 
core subunit of the SS18-SSX fusion protein complex. In the second paper, we applied a 
proximity ligation assay to screen for novel compounds that can disrupt the interaction of 
SS18-SSX with TLE1. The following findings were demonstrated: 
• The interaction of SS18-SSX with TLE1 is specific for synovial sarcomas. 
• SS18-SSX/TLE1 interactions are sensitive to class I HDAC inhibitors and a novel 
compound designated SXT1596. 
• SXT1596 re-establishes normal cell signaling in synovial sarcoma. 
• PLA can be utilised in drug screenings to assess the capability of drugs to disrupt the 
relevant functional protein-protein interaction.  
In the third paper, we further evaluated the activity of sirtuin inhibitor tenovin-6 and AGK2 
in SSs and explored the mechanism of action of these 2 compounds. We concluded from the 
study that:  
• SIRT1 and SIRT2 are involved in synovial sarcoma tumourigenesis that is driven by 
the SS18-SSX fusion protein complex. 
• Tenovin-6 and AGK2 dissociate the interactions between SIRT1/SIRT2 and the 
fusion protein SS18-SSX, the dissociation activities of the 2 compounds are time 
dependent. 
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5 FUTURE PERSPECTIVES 
 
The translocation t(X;18) was first described and linked with synovial sarcoma in 1986. Since 
then a lot of effort have been made to investigate the role of this translocation in synovial 
sarcoma. It has been elucidated nowadays that the fusion product SS18-SSX is the driving 
event for synovial sarcoma tumourigenesis. It functions predominantly in transcriptional 
regulation due to protein-protein interactions and associations with important chromatin 
remodelling complexes, resulting in aberrant gene expressions and oncogenic properties. 
Considering the limited benefit of the current therapies for the patients with synovial 
sarcoma, targeting the fusion oncoprotein SS18-SSX and the related oncoprotein complex 
shows great therapeutic potential. Therefore, continued studies that identify component 
proteins and target genes of the SS18-SSX complex are essential for the development of 
novel therapeutics for synovial sarcoma.  
Apart from PLA and co-immunoprecipitation, there are several methods that assess protein-
protein interactions, such as pull-down assay, label transfer, bimolecular fluorescence 
complementation (BiFC) and fluorescence resonance energy transfer (FRET). Each of the 
approaches has its own strengths and weaknesses. In the short-term perspective of our 
project, we expect that combination of different methods can be used to confirm the 
interactions of SIRT1/SIRT2 and SS18-SSX in synovial sarcoma. Mass spectrophotometry 
can be used to elucidate the components of SS18-SSX complex. Furthermore, chromatin 
immunoprecipitation and DNA sequencing (Chip-seq assay) could be performed to identify 
the genes directly targeted by the SS18-SSX transcriptional complex. The identified proteins 
and genes can be evaluated in an in vitro transfection model using CRISPR/Cas 9 system. 
Protein-protein interaction based drug screening should elucidate more compounds that target 
specific SS18-SSX complex components. The potential of the new agents can be further 
tested in an in vivo model. 
In the long-term perspective, we believe that by identifying the aberrantly recruited proteins 
to the SS18-SSX fusion oncoprotein, our understanding of the synovial sarcoma will continue 
to increase. Combining the information gained from this thesis study with the knowledge to 
be gained from future studies as mentioned above, assisted with the technical advances in 
detecting and visualising protein-protein interactions and our ability to design new 
therapeutic strategies for synovial sarcoma patients will likely lay down a fruitful foundation 
for finding effective novel therapeutic agents.  
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